Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 39Melanoma 34Gliosarcoma 34Brain Neoplasms 33Breast Neoplasms 31Lymphoma 24Neoplasm Metastasis 23Astrocytoma 23Colonic Neoplasms 20Multiple Myeloma 19Leukemia, Myeloid, Acute 19Leukemia 19Carcinoma, Non-Small-Cell Lung 19Prostatic Neoplasms 18Lymphoma, Non-Hodgkin 18Colorectal Neoplasms 18Central Nervous System Neoplasms 18Carcinoma, Renal Cell 18Rectal Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Leukemia, Lymphocytic, Chronic, B-Cell 16Hodgkin Disease 16Squamous Cell Carcinoma of Head and Neck 15Oligodendroglioma 15Pancreatic Neoplasms 14Myelodysplastic Syndromes 14Lung Neoplasms 14Sarcoma 13

Interventions

molibresib 1etoposide phosphate 1Platinum 1Etoposide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × NIH × Metastatic NUT Carcinoma × Clear all
NCT04116359 2020-09-28

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn

Metastatic NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡